Identification

Name
Etoricoxib
Accession Number
DB01628  (DB07166)
Type
Small Molecule
Groups
Approved, Investigational
Description

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.

Structure
Thumb
Synonyms
  • 5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
  • 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
  • 5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine
  • ETORICOXIB
  • Etoricoxibum
  • L791456
External IDs
L-791456 / MK-0663 / MK-663
Product Ingredients
IngredientUNIICASInChI Key
Etoricoxib hydrochloride138Y28RY5E202409-40-3NNGHGPAKTWAHHB-UHFFFAOYSA-N
International/Other Brands
Algix / Arcoxia / Coxyveen (Solmarc Lifesciences) / Etorix / Nucoxia / Tauxib
Categories
UNII
WRX4NFY03R
CAS number
202409-33-4
Weight
Average: 358.842
Monoisotopic: 358.054276131
Chemical Formula
C18H15ClN2O2S
InChI Key
MNJVRJDLRVPLFE-UHFFFAOYSA-N
InChI
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
IUPAC Name
5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine
SMILES
CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O

Pharmacology

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Pharmacodynamics

Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.

Mechanism of action

Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces prostaglandins (PGs) generation from arachidonic acid.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Bioavailability is 100% following oral administration.

Volume of distribution
Not Available
Protein binding

92%

Metabolism

Hepatic, primarily via CYP3A4.

Route of elimination
Not Available
Half life

22 hours

Clearance
Not Available
Toxicity

This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Etoricoxib Action PathwayDrug action
Etoricoxib Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etoricoxib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabEtoricoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Etoricoxib can be increased when it is combined with Abiraterone.Approved
AcebutololEtoricoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolEtoricoxib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Etoricoxib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etoricoxib.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Etoricoxib.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Etoricoxib.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.Approved
AliskirenEtoricoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Etoricoxib.Experimental
AlprenololEtoricoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etoricoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideEtoricoxib may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Etoricoxib.Approved
AncrodEtoricoxib may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etoricoxib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etoricoxib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.Approved, Investigational
Antithrombin III humanEtoricoxib may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Etoricoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanEtoricoxib may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Etoricoxib.Investigational
ApramycinEtoricoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Etoricoxib.Approved, Investigational
AprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinEtoricoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinEtoricoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEtoricoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEtoricoxib may decrease the antihypertensive activities of Arotinolol.Investigational
ArtemetherThe metabolism of Etoricoxib can be decreased when combined with Artemether.Approved
AsenapineEtoricoxib may decrease the antihypertensive activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Etoricoxib.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Atamestane.Investigational
AtazanavirThe metabolism of Etoricoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololEtoricoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.Approved, Investigational
AzithromycinThe metabolism of Etoricoxib can be decreased when combined with Azithromycin.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Etoricoxib.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.Approved, Investigational
BazedoxifeneEtoricoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminEtoricoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Etoricoxib.Approved, Investigational
BefunololEtoricoxib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinEtoricoxib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Etoricoxib.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Etoricoxib.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etoricoxib.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Etoricoxib.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Etoricoxib.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Etoricoxib.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etoricoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Etoricoxib can be decreased when combined with Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Etoricoxib.Approved, Investigational
BevantololEtoricoxib may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Etoricoxib.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
BisoprololEtoricoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEtoricoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Etoricoxib can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololEtoricoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Etoricoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Etoricoxib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etoricoxib.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etoricoxib.Investigational
BucindololEtoricoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Etoricoxib.Approved
BufexamacThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Bufexamac.Approved, Experimental
BufuralolEtoricoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Etoricoxib.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Etoricoxib.Approved
BupranololEtoricoxib may decrease the antihypertensive activities of Bupranolol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Etoricoxib.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etoricoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Etoricoxib can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Captopril.Approved
CarbamazepineThe metabolism of Etoricoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Etoricoxib.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.Approved, Vet Approved, Withdrawn
CarteololEtoricoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEtoricoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etoricoxib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.Approved, Investigational
CeliprololEtoricoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Etoricoxib.Approved, Withdrawn
CertoparinEtoricoxib may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
ChlorotrianiseneEtoricoxib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpromazineThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.Approved
CholecalciferolThe metabolism of Etoricoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etoricoxib.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cimicoxib.Investigational
CinacalcetThe metabolism of Etoricoxib can be decreased when combined with Cinacalcet.Approved
CinoxacinEtoricoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinEtoricoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Etoricoxib.Approved
ClarithromycinThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.Approved
ClobazamThe metabolism of Etoricoxib can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClomipramineThe metabolism of Etoricoxib can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Etoricoxib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etoricoxib.Vet Approved
CloranololEtoricoxib may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneEtoricoxib may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Etoricoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Etoricoxib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Etoricoxib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Etoricoxib can be decreased when combined with Cocaine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Etoricoxib.Approved, Investigational
Conjugated estrogensEtoricoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Etoricoxib can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Etoricoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Etoricoxib.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etoricoxib.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Etoricoxib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinEtoricoxib may increase the thrombogenic activities of Daidzein.Experimental
DalteparinEtoricoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEtoricoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Etoricoxib.Investigational
DarexabanEtoricoxib may increase the anticoagulant activities of Darexaban.Investigational
DarifenacinThe metabolism of Etoricoxib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Etoricoxib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Delapril.Investigational
DelavirdineThe metabolism of Etoricoxib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Etoricoxib can be decreased when combined with Desipramine.Approved, Investigational
DesirudinEtoricoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Desvenlafaxine is combined with Etoricoxib.Approved, Investigational
DexamethasoneThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etoricoxib.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Etoricoxib.Experimental
DextranEtoricoxib may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinEtoricoxib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etoricoxib.Approved, Vet Approved
DicoumarolEtoricoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolEtoricoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolEtoricoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Etoricoxib.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etoricoxib.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Etoricoxib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Etoricoxib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Etoricoxib.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Etoricoxib.Approved, Investigational
DihydrostreptomycinEtoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Etoricoxib can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Etoricoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etoricoxib.Approved
DiphenadioneEtoricoxib may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Etoricoxib can be decreased when combined with Dosulepin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Etoricoxib.Approved
DoxycyclineThe metabolism of Etoricoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Etoricoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneEtoricoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Etoricoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etoricoxib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Etoricoxib.Investigational
Edetic AcidEtoricoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEtoricoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Etoricoxib can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EliglustatThe metabolism of Etoricoxib can be decreased when combined with Eliglustat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalaprilat.Approved
EnoxacinEtoricoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinEtoricoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Etoricoxib.Experimental
EnzalutamideThe serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.Approved
EpanololEtoricoxib may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolEtoricoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Etoricoxib.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Etoricoxib.Experimental
EplerenoneEtoricoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilin.Approved
EquolEtoricoxib may increase the thrombogenic activities of Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Etoricoxib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Etoricoxib.Approved
ErythromycinThe metabolism of Etoricoxib can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEtoricoxib may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EsmololEtoricoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolEtoricoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateEtoricoxib may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateEtoricoxib may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateEtoricoxib may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolEtoricoxib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedEtoricoxib may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneEtoricoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Etoricoxib.Experimental
Ethinyl EstradiolEtoricoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Etoricoxib.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Etoricoxib.Withdrawn
EtravirineThe metabolism of Etoricoxib can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etoricoxib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Etoricoxib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Etoricoxib.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etoricoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etoricoxib.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Etoricoxib.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Etoricoxib.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Etoricoxib.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etoricoxib.Approved, Investigational
FleroxacinEtoricoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etoricoxib.Approved, Withdrawn
FloxuridineThe metabolism of Etoricoxib can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Etoricoxib can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fludrocortisone.Approved, Investigational
FluindioneEtoricoxib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineEtoricoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Etoricoxib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Etoricoxib.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Etoricoxib.Approved, Investigational
FluorouracilThe metabolism of Etoricoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Etoricoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etoricoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etoricoxib.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Etoricoxib.Approved
FluvoxamineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluvoxamine is combined with Etoricoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxEtoricoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etoricoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Etoricoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Etoricoxib can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinEtoricoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
Fusidic AcidThe serum concentration of Etoricoxib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateEtoricoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEtoricoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEtoricoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etoricoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Etoricoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinEtoricoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEtoricoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinEtoricoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinEtoricoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEtoricoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Etoricoxib.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Etoricoxib.Approved
GrepafloxacinEtoricoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Etoricoxib.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Etoricoxib.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Etoricoxib is combined with HE3286.Investigational
HeparinEtoricoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolEtoricoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Etoricoxib.Investigational
HydralazineEtoricoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Etoricoxib.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Etoricoxib.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Etoricoxib.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
Hygromycin BEtoricoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Ibandronate.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Etoricoxib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Etoricoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Etoricoxib.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Etoricoxib can be decreased when combined with Idelalisib.Approved
IdraparinuxEtoricoxib may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
ImatinibThe metabolism of Etoricoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Etoricoxib.Experimental
ImipramineThe metabolism of Etoricoxib can be decreased when combined with Imipramine.Approved
IndalpineIndalpine may increase the antiplatelet activities of Etoricoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.Approved
IndenololEtoricoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Etoricoxib can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Etoricoxib.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etoricoxib.Withdrawn
IrbesartanThe metabolism of Etoricoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Etoricoxib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Etoricoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinEtoricoxib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Etoricoxib can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etoricoxib.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Etoricoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Etoricoxib can be increased when it is combined with Ivacaftor.Approved
KanamycinEtoricoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etoricoxib.Experimental
KetoconazoleThe metabolism of Etoricoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.Approved
LabetalolEtoricoxib may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
LandiololEtoricoxib may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Etoricoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etoricoxib.Approved, Investigational
LepirudinEtoricoxib may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
LetaxabanEtoricoxib may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololEtoricoxib may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololEtoricoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEtoricoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etoricoxib.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Etoricoxib.Approved, Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.Experimental
LobeglitazoneThe metabolism of Etoricoxib can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinEtoricoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Etoricoxib.Experimental
LopinavirThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Etoricoxib can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Etoricoxib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Etoricoxib.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etoricoxib.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etoricoxib.Approved, Investigational
LuliconazoleThe serum concentration of Etoricoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Etoricoxib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Etoricoxib can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etoricoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Etoricoxib.Vet Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Etoricoxib.Illicit, Investigational, Withdrawn
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etoricoxib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Etoricoxib is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.Approved
MelagatranEtoricoxib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.Approved, Vet Approved
MepindololEtoricoxib may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.Approved
MestranolEtoricoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etoricoxib.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Etoricoxib.Experimental
MethadoneThe metabolism of Etoricoxib can be decreased when combined with Methadone.Approved
MethallenestrilEtoricoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.Approved
MethotrimeprazineThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoricoxib.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Etoricoxib.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Etoricoxib.Approved
MetipranololEtoricoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.Approved
MetoprololEtoricoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Etoricoxib.Experimental
MexiletineThe metabolism of Etoricoxib can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe metabolism of Etoricoxib can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Etoricoxib can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinEtoricoxib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Etoricoxib can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Etoricoxib.Approved, Experimental
MifepristoneThe serum concentration of Etoricoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Etoricoxib.Approved, Investigational
MirabegronThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etoricoxib.Approved
MitotaneThe serum concentration of Etoricoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etoricoxib.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Etoricoxib.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etoricoxib.Approved
MoxestrolEtoricoxib may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinEtoricoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.Approved
NabiloneThe metabolism of Etoricoxib can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.Approved
NadololEtoricoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEtoricoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etoricoxib.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etoricoxib.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Etoricoxib.Investigational
Nalidixic AcidEtoricoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etoricoxib.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Etoricoxib is combined with NCX 1022.Investigational
NeamineEtoricoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololEtoricoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Etoricoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Etoricoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinEtoricoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etoricoxib.Approved, Investigational
NetilmicinEtoricoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Etoricoxib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Etoricoxib can be increased when combined with Nevirapine.Approved
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Etoricoxib.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Etoricoxib.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Etoricoxib.Experimental
NilotinibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Etoricoxib.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Etoricoxib.Investigational
NorfloxacinEtoricoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinEtoricoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Etoricoxib can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Etoricoxib is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Etoricoxib.Vet Approved
OsimertinibThe serum concentration of Etoricoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanEtoricoxib may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.Approved
Oxolinic acidEtoricoxib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololEtoricoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib.Approved, Withdrawn
PalbociclibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Etoricoxib.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Etoricoxib can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Paroxetine is combined with Etoricoxib.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Etoricoxib.Approved, Investigational
PazufloxacinEtoricoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEtoricoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololEtoricoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateEtoricoxib may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Etoricoxib can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Etoricoxib.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Perindopril.Approved
PhenindioneEtoricoxib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Etoricoxib can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonEtoricoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etoricoxib.Approved, Vet Approved
PhenytoinThe metabolism of Etoricoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.Approved, Investigational
PindololEtoricoxib may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidEtoricoxib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Etoricoxib.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etoricoxib.Approved, Investigational
Piromidic acidEtoricoxib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Etoricoxib.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Etoricoxib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Etoricoxib.Approved, Investigational
Platelet Activating FactorEtoricoxib may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinEtoricoxib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateEtoricoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etoricoxib.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pomalidomide.Approved
Potassium CitrateEtoricoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololEtoricoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etoricoxib.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Etoricoxib.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone sulfate.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Etoricoxib.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Etoricoxib.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Etoricoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Etoricoxib can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Etoricoxib.Experimental
PromazineThe metabolism of Etoricoxib can be decreased when combined with Promazine.Approved, Vet Approved
PromestrieneEtoricoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etoricoxib.Approved, Investigational
PropafenoneEtoricoxib may decrease the antihypertensive activities of Propafenone.Approved
PropranololEtoricoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Etoricoxib.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Etoricoxib.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etoricoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etoricoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Etoricoxib.Vet Approved
Protein CEtoricoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanEtoricoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEtoricoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEtoricoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Etoricoxib.Investigational
PuromycinEtoricoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Etoricoxib can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Quinapril.Approved, Investigational
QuinestrolEtoricoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.Approved
QuinidineThe metabolism of Etoricoxib can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Etoricoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ramipril.Approved
RanolazineThe metabolism of Etoricoxib can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinEtoricoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Etoricoxib can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Etoricoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Etoricoxib can be increased when combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Etoricoxib.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Etoricoxib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanEtoricoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etoricoxib.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Etoricoxib can be decreased when combined with Rolapitant.Approved, Investigational
RosoxacinEtoricoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Etoricoxib can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinEtoricoxib may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etoricoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etoricoxib.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.Experimental
SaquinavirThe metabolism of Etoricoxib can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etoricoxib.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Etoricoxib.Approved, Investigational
SecobarbitalThe metabolism of Etoricoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolEtoricoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Etoricoxib.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etoricoxib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Etoricoxib.Investigational
SertralineSertraline may increase the antiplatelet activities of Etoricoxib.Approved
SildenafilThe metabolism of Etoricoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Etoricoxib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Etoricoxib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Etoricoxib.Approved
SisomicinEtoricoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinEtoricoxib may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Etoricoxib.Approved
SorafenibThe metabolism of Etoricoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolEtoricoxib may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinEtoricoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Etoricoxib.Investigational
St. John's WortThe serum concentration of Etoricoxib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Etoricoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinEtoricoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Etoricoxib can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.Approved
SulfisoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etoricoxib.Approved, Investigational
SulodexideEtoricoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Etoricoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Etoricoxib.Experimental
Synthetic Conjugated Estrogens, AEtoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BEtoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusEtoricoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Etoricoxib.Approved
TalinololEtoricoxib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etoricoxib.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etoricoxib.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etoricoxib.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Etoricoxib can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Etoricoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.Approved, Investigational
TemafloxacinEtoricoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Etoricoxib.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Etoricoxib.Vet Approved
TerbutalineEtoricoxib may decrease the antihypertensive activities of Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Etoricoxib.Experimental
TeriflunomideThe serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.Approved
TertatololEtoricoxib may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Etoricoxib.Investigational
TheophyllineThe metabolism of Etoricoxib can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.Approved
TiboloneEtoricoxib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Etoricoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololEtoricoxib may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etoricoxib.Investigational
TioclomarolEtoricoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Etoricoxib can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tixocortol.Approved, Withdrawn
TobramycinEtoricoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Etoricoxib can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Etoricoxib.Approved
TopiroxostatThe metabolism of Etoricoxib can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Etoricoxib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEtoricoxib may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Etoricoxib.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Etoricoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Etoricoxib.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Trolamine salicylate.Approved
TrovafloxacinEtoricoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinEtoricoxib may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etoricoxib.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.Approved, Investigational, Withdrawn
ValsartanThe metabolism of Etoricoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinEtoricoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VemurafenibThe serum concentration of Etoricoxib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Venlafaxine is combined with Etoricoxib.Approved
VerapamilThe metabolism of Etoricoxib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Etoricoxib can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEtoricoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEtoricoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Etoricoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etoricoxib.Approved, Investigational
ZeranolEtoricoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etoricoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Etoricoxib.Withdrawn
ZiprasidoneThe metabolism of Etoricoxib can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etoricoxib.Withdrawn
ZucapsaicinThe metabolism of Etoricoxib can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia, "PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB." U.S. Patent US20120232281, issued September 13, 2012.

US20120232281
General References
Not Available
External Links
Human Metabolome Database
HMDB0015565
KEGG Drug
D03710
KEGG Compound
C11718
PubChem Compound
123619
PubChem Substance
46504505
ChemSpider
110209
BindingDB
50072064
ChEBI
6339
ChEMBL
CHEMBL416146
Therapeutic Targets Database
DAP000738
PharmGKB
PA164776853
HET
5CH
Wikipedia
Etoricoxib
ATC Codes
M01AH05 — Etoricoxib
PDB Entries
3cfl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentMuscle pains1
1CompletedTreatmentPain1
1RecruitingTreatmentTuberculosis1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRheumatoid Arthritis1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2TerminatedTreatmentComplex Regional Pain Syndrome Type II / Peripheral Nerve Injury (PNI) / Polyneuropathies / Postherpetic Neuralgia / Radicular syndrome1
2TerminatedTreatmentOsteoarthritis, Hip / Pain / Postoperative pain1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3CompletedTreatmentAcute Pain Following a Total Abdominal Hysterectomy1
3CompletedTreatmentAnkylosing Spondylitis (AS)2
3CompletedTreatmentAnterior Cruciate Ligament Injury1
3CompletedTreatmentArthroplasties Hip Replacement / Osteoarthritis, Hip / Perioperative Blood Loss1
3CompletedTreatmentDysmenorrhea2
3CompletedTreatmentHysterectomy / Oophorectomy / Postoperative pain / Tubal Excision1
3CompletedTreatmentKnee Osteoarthritis (Knee OA)1
3CompletedTreatmentOsteoarthritis (OA)4
3CompletedTreatmentPostoperative Dental Pain1
3CompletedTreatmentPostoperative pain3
3CompletedTreatmentRheumatoid Arthritis2
3CompletedTreatmentRheumatoid Arthritis,Osteoarthritis1
3RecruitingTreatmentPrimary Hypertrophic Osteoarthropathy1
3TerminatedTreatmentSoft Tissue Injuries of the Shoulder / Tenosynovitis and Bursitis Affecting the Shoulder1
4Active Not RecruitingNot AvailableAcute Gouty Arthritis / Ankylosing Spondylitis (AS) / Arthritis / Osteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionFasting / Fasting Headache / Headaches / Ramadan Headache1
4CompletedPreventionOssification, Heterotopic1
4CompletedTreatmentAchilles Tendinopathy1
4CompletedTreatmentCyclooxygenase Two Inhibitors / Etoricoxib / Periodontitis / Saliva / Superoxide Dismutase1
4CompletedTreatmentLaparoscopic Surgery for Appendicitis / Laparoscopic Surgery for Cholecystitis / Laparoscopic Surgery for Ovarian Cysts1
4CompletedTreatmentOsteoarthritis (OA) / Pain1
4CompletedTreatmentPain2
4CompletedTreatmentPost-operational Pain1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentRupture of Anterior Cruciate Ligament1
4TerminatedPreventionPain1
4TerminatedTreatmentPost-Operative Pain1
4Unknown StatusPreventionHeadaches1
4Unknown StatusTreatmentDental Extraction1
4Unknown StatusTreatmentFibromyalgia1
4Unknown StatusTreatmentLow Back Pain (LBP)1
4Unknown StatusTreatmentPain, Acute1
4Unknown StatusTreatmentNeurocostal neuralgia / Postherpetic Neuralgia1
4Unknown StatusTreatmentRheumatoid Arthritis1
4WithdrawnTreatmentHallux Valgus / Postoperative pain1
4WithdrawnTreatmentOsteoarthritis (OA)1
4WithdrawnTreatmentSprains1
Not AvailableActive Not RecruitingNot AvailableSpondylarthropathies; Spondylitis, Ankylosing1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableCompletedNot AvailableOsteoarthritis (OA)1
Not AvailableCompletedBasic ScienceAsthma Bronchial1
Not AvailableCompletedPreventionColor Changes During Tooth Formation1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedTreatmentAdverse Anesthesia Outcome1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentProliferative Diabetic Retinopathy (PDR)1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Anesthesia Morbidity / Breast Neoplasm Female / Regional Anesthesia / Regional Anesthesia Morbidity1
Not AvailableRecruitingTreatmentCervical Osteoarthritis1
Not AvailableUnknown StatusTreatmentEdema / Pain / Trismus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00328 mg/mLALOGPS
logP3.7ALOGPS
logP2.79ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)19.69ChemAxon
pKa (Strongest Basic)4.96ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.04 m3·mol-1ChemAxon
Polarizability36.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9776
Blood Brain Barrier+0.9399
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.845
P-glycoprotein inhibitor INon-inhibitor0.7624
P-glycoprotein inhibitor IINon-inhibitor0.9869
Renal organic cation transporterNon-inhibitor0.8267
CYP450 2C9 substrateNon-substrate0.6702
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.506
CYP450 1A2 substrateInhibitor0.6415
CYP450 2C9 inhibitorInhibitor0.8528
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorInhibitor0.9087
CYP450 3A4 inhibitorInhibitor0.585
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8848
Ames testNon AMES toxic0.7952
CarcinogenicityNon-carcinogens0.6856
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.4100 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9934
hERG inhibition (predictor II)Non-inhibitor0.8582
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Bipyridines and oligopyridines
Direct Parent
Bipyridines and oligopyridines
Alternative Parents
Phenylpyridines / Benzenesulfonyl compounds / Methylpyridines / Aryl chlorides / Sulfones / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 2 more
Substituents
Bipyridine / 3-phenylpyridine / Benzenesulfonyl group / Methylpyridine / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Sulfone / Sulfonyl
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfone, organochlorine compound, bipyridines (CHEBI:6339)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P: Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3. [PubMed:17164136]
  4. FitzGerald GA: COX-2 in play at the AHA and the FDA. Trends Pharmacol Sci. 2007 Jul;28(7):303-7. Epub 2007 Jun 18. [PubMed:17573128]
  5. Yuan Y, Hunt RH: Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47. [PubMed:17691997]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM: Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. [PubMed:18840026]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on August 30, 2007 09:49 / Updated on August 02, 2018 04:39